1 / 40

The Breast Basic Science Conference Cindy M Deutmeyer MUSC Department of Surgery May 25 th , 2010

The Breast Basic Science Conference Cindy M Deutmeyer MUSC Department of Surgery May 25 th , 2010. Anatomy. Develop along paired mammary ridges Primary bud  15-20 secondary buds epithelial cords

clay
Download Presentation

The Breast Basic Science Conference Cindy M Deutmeyer MUSC Department of Surgery May 25 th , 2010

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The BreastBasic Science ConferenceCindy M DeutmeyerMUSC Department of SurgeryMay 25th, 2010

  2. Anatomy • Develop along paired mammary ridges • Primary bud  15-20 secondary buds epithelial cords • Major (lactiferous) ducts empty into shallow mammary pit  mesenchyme proliferates  elevation above skin nipple • 4% Inverted nipples (pit not elevated above skin) • Puberty: Estrogen & Progesterone proliferation of epithelial & connective tissue elements • Polymastia: accessory breast • Amastia: absence of breast • Poland’s Sx: hypoplasia or absence of breast w/rib, chest wall, & upper extremity defects • Polythelia: accessory nipples (1%)

  3. Anatomy • 3 tissue types: fatty, fibrous, glandular • 15-20 lobes composed of several Lobules • Each lobe drains into Lactiferous Duct/Sinus, and eventually nipple • Cooper’s suspensory ligaments: fibrous connective tissue bands, perpendicular to dermis, structural support

  4. Breast Boundaries • Superior Clavicle, 2nd rib • Inferior Inframammary Fold, 6th rib • Medial Sternum (lateral border) • Lateral Anterior axillary line, Latissimus dorsi • Posterior Pectoral fascia * Axillary tail of Spence

  5. Blood Supply & Lymphatics • Internal Mammary a. perforators • Intercostal a. • Axillary a. branches * Lateral thoracic * Highest thoracic • Thoracoacromial a. branches • 3 principal groups of veins * Internal thoracic v. perforators * Intercostal v. perforators * Axillary v. tributaries • Batson’s plexus: surrounds vertebral column • 6 axillary lymph node groups • Receive 75% lymph drainage • 3 axillary lymph node levels * Level I: lateral to Pec minor * Level II: deep to Pec minor * Level III: medial to Pec minor

  6. Cases

  7. Case 1: Breast Pain 35 y.o. G1P1 presents with complaints of pain in breasts. Pain is bilateral, diffuse. Feels swollen. POBHx- SVD x 1 PGYNHx- regular menses PMHx/PSHx- negative MEDS- none FHx- noncontributory

  8. Breast Pain Differential diagnosis • Fibrocystic changes • Mastalgia/mastodynia • Cyst • Duct obstruction • Inflammation/infection- mastitis • Trauma

  9. Breast PainFibrocystic change • Most common of benign breast conditions • Replaces “fibrocystic disease” • Multiple tender breast masses • May be cyclic in nature • May be exaggerated response to hormones • Usually present as cyclic, bilateral pain and breast engorgement • Pain diffuse, often radiates to shoulders or upper arms • Prominent thickened plaques of breast tissue, often in upper outer quadrants

  10. Breast PainFibrocystic change Management • Fine-needle aspiration- diagnostic & therapeutic • Ultrasound w/needle biopsy if bloody fluid, residual mass, cyst recurrence • Restrict caffeine, foods containing methylxanthines • OCPs • Pain medications- ibuprofen, salicylates, acetaminophen • Diuretics • Danazol • Bromocriptine

  11. Breast PainInfection/inflammation • Presents with pain, erythema, fever • Lactational mastitis- • Occurs postpartum, Staph aureus or MRSA colonization • Management- ultrasound, antibiotics (PCN), continue breast feeding or pumping (if not MRSA); incision and drainage of abscess if virulent strain/nosocomial • Nonlactational abscess- • Can be due to fistula, tuberculosis, fungi, carcinoma • Mammo & Ultrasound req • Zuska’s Dz: recurrent retroareolar infections

  12. Case 2: Nipple Discharge 35 y.o. G1P1 presents with complaints of spontaneous nipple discharge. Right breast, bloody discharge POBHx- SVD x 1 PGYNHx- benign PMHx/PSHx- negative MEDS- OCPs FHx- noncontributory

  13. Nipple discharge Differential diagnosis • Breast lesions- • intraductal papilloma, ductal ectasia, fibrocystic changes, breast abscess • Drug induced- • phenothiazines, reserpine, methyldopa, imipramine, amphetamine, OCPs • CNS lesions- • pituitary adenoma, empty sella, hypothalamic tumor • Medical conditions- • Cushings, hypothyroid, chronic renal failure • Carcinoma • Idiopathic

  14. Nipple discharge Workup • Exam • Labs- Prolactin, TSH • Mammogram • Cytologic evaluation of discharge- not very useful • Ductography

  15. Nipple Discharge Intraductal papilloma • Epithelial tumors arising in ducts of breast • Main cause of nipple discharge in nonpregnant or nonlactating women • Usually women age 40-45 • Benign, extremely small increased cancer risk • Size 2-5 mm, usually not palpable • Present with spontaneous, bloody, serous or cloudy nipple discharge • Management- excisional biopsy

  16. Nipple DischargeDuctal ectasia • Second most common cause of nipple discharge • Older patients • Increase in glandular secretion • Discharge thick, gray/black color • Can lead to nipple retraction and breast mass • Management- medical, icepacks, anti-inflammatory agents, broad spectrum antibiotics, surgery if abscess or mass present

  17. Nipple discharge *Bad signs • Serous, serosanguinous, or watery discharge • Associated with mass • Unilateral • Single duct • Positive cytology • Positive mammography • Age >50 yrs old

  18. Case 3: Breast Lump 45 y.o. G2P2 presents with complaints of mass in left breast. Noticed on self exam.

  19. Breast Lump History • Length of time present • Presence of pain • Change in size or texture • Relationship to menstrual cycle • Nipple discharge • Family history of breast or ovarian cancer and ages • Age at first live birth, menarche, menopause

  20. Breast Lump Differential diagnosis • Fibroadenoma • Macrocysts • Galactoceles • Lipoma • Abscess • Rare causes- sclerosing adenosis, cystosarcoma phyllodes • Malignancy

  21. Breast Lump Work up • Exam • Imaging- • Diagnostic mammogram- less sensitive in younger women due to breast density • Ultrasound- can distinguish cystic lesions from solid masses (require further evaluation) • Biopsy- GET A TISSUE DIAGNOSIS!! • Fine needle aspiration, Core needle biopsy, Open biopsy

  22. Breast MassFibroadenoma • Second most common benign breast disease, most common benign solid tumor • Firm, painless, mobile breast mass, 2-3 cm, commonly in upper outer quadrants • Usually women aged 20-40 • Multiple in 15-20% of patients • Slow growing, do not regress spontaneously • Can be stimulated by exogenous estrogen, progesterone, lactation, pregnancy • Management- watch & wait, biopsy, or excision

  23. Breast Mass Macrocysts • Most often women age 35-50 • Fluid-filled sac • Often solitary but can be multiple • Can have associated nipple discharge • Aspiration for diagnosis and therapy Galactocoele • Milk-filled cyst • Usually follows lactation • Firm, tender mass • Usually in upper quadrants • Diagnostic aspiration often curative Lipoma • Nontender • No associated skin or nipple changes • Usually postmenopausal women • Management- biopsy or excision

  24. Breast cancer • >180,000 new cases per year (estimated from 2008) • 80% in women >50 yrs old, 20% in women <50 yrs old • >40,000 deaths per year (estimated from 2008) • Second leading cause of cancer-related death in women • Lifetime risk of breast cancer 12% • One in eight women will develop breast cancer • Increasing incidence but decreasing mortality • Lower incidence in Asian/Pacific Islanders, Hispanic/Latina, American Indian/Alaska natives • Higher mortality in African Americans (though lower lifetime risk) • Incidence & Mortality lowest in Asia/Africa, underdeveloped nations, those who have not adopted the Westernized reproductive & dietary patterns

  25. Breast cancer Risk factors (21% of cases) Factor Relative Risk + FHx 1.2-3.0 Menstrual Hx (menarche <12, >40 yrs total) 1.3-2.0 OCP use No effect Estrogen replacement <10 yrs No effect Pregnancy (1st >35 y.o., nulliparous) 2.0-3.0 Contralateral breast cancer 5.0 Ovarian/uterine cancer 2.0

  26. Breast cancer Classification • Ductal carcinoma (>80% of cancers) • In situ: progresses to invasive cancer; cribiform, solid, comedo types; classified by nuclear grade & necrosis; calcifications on mammo • Medullary carcinoma: soft, hemorrhagic, BRCA1 • Colloid/Mucinous carcinoma: elderly, bulky, gelatinous • Tubular: peri- early menopausal, rarely metastasizes • Papillary: 7th decade, nonwhite women, small, rarely metastasize • Inflammatory: dermal lymphatics invaded, erythema & warmth • Paget’s disease: eczematous lesion on nipple, usu assoc w/underlying malignancy, • Apocrine duct

  27. Breast Cancer • Lobular carcinoma • In situ: only in female breast; calcifications on mammo in adjacent tissue; 12x more common in white women; not premalignant lesion, but marker for future development of invasive cancer • Infiltrative- multifocal, multicentric, bilateral; no distinct mass; signet-ring cell variant • Rare variants • Juvenile, epidermoid, carcinoid, squamous cell, spindle cell • Sarcoma and carcinosarcoma • Cystosarcoma phyllodes, angiosarcoma, malignant lymphoma

  28. Breast cancer Symptoms • 33% discovered by self-exam • Breast enlargement or asymmetry • Nipple changes, retraction, or discharge • Ulceration or erythema of skin • Axillary mass • Musculoskeletal complaints • Early- mammo abnormality, painless, mobile tumor

  29. Breast cancer • Screening Mammogram • Annually every year >age 40, before age 40 in selected high-risk patients, w/annual clinical breast exam • Start 5-10 yrs before age of affected family member • Decreases mortality by up to 33% (not proven in women age 40-49) • 10% False-positive rate • 7% False-negative rate • Clustered microcalcifications, fine/stippled calcium around a lesion, solid mass, & asymmetric tissue thickening are suspicious for cancer • If equivocal findings on mammo, get ultrasound

  30. Hereditary breast cancers • Hereditary breast cancers 5-10% of breast cancers • Appropriate counseling must be provided to patient and family before testing for BRCA mutations • BRCA1 mutation (Breast & Ovary; some colon & prostate) • AD inheritance, chromosome 17q21, thought to be tumor suppressor gene • lifetime risk of breast cancer 90%, lifetime risk of ovarian cancer 40% • Early age onset breast cancer • Bilateral • Usu invasive ductal CA, poorly differentiated, hormone receptor (-) • BRCA2 mutation (Breast, less Ovary; some GI, Prostate, Melanoma, & Pancreas) • chromosome 13q12, early age of onset, male breast cancer • lifetime risk of breast cancer is 85%, lifetime risk of ovarian cancer 20% • Well differentiated, hormone receptor (+) • Ashkenazi Jews, Icelandic & Finnish populations • Clinical breast exam Q6 mo, w/yearly mammo (MRI) & transvaginal ultrasound w/CA-125 level starting at age 25 (if options below not excercised) • Prophylactic mastectomy after child-bearing • Prophylactic oophorectomy after age 40

  31. Breast Cancer Staging • Clinical staging based on physical exam • Pathological staging more accurate • TNM Staging system • T1:<2cm, T2:>2cm, T3:>5, T4: any size + involvement of chest wall or skin • N0:0 nodes, N1:movable, N2:fixed, N3:infraclavicular, supraclavicular, internal mammary • M0:no mets, M1:mets • Most important predictor of survival is…

  32. Breast Cancer Treatment • In Situ (Stage 0) • LCIS:observation, chemoprevention w/Tamoxifen, & bilateral total mastectomy • DCIS: >4 cm disease or disease in >1quadrant = mastectomy • Low-grade DCIS <0.5cm: Needle-localized Lumpectomy alone if margins are widely free of disease • High-grade DCIS or larger size: Lumpectomy w/Adjuvant radiation tx, or Mastectomy • Recurrence rate greater (9%) w/Lumpectomy + Rad, but mortality rate similar to mastectomy • Risk for recurrence increases with: >2.5 cm size, comedo type, close margins

  33. Breast Cancer Treatment • Early Invasive (Stage I, IIA, or IIB) • Mastectomy with assessment of axillary lymph node status • Breast conserving surgery with assessment of axillary lymph node status + radiation (standard of care) • Sentinel lymph node bx is now standard care for women with clinically negative nodes; metastatic disease in an axillary or sentinel lymph node requires full axillary dissection • Contraindications to sentinel node bx: T3/T4, Inflammatory CA, palpable axillary nodes, pregnancy, DCIS without mastectomy, prior axillary surgery, after neoadjuvant chemo, prior nononcologic breast surgery • Relative contraindications to breast conserving tx: prior radiation, positive surgical margins after re-excision, multicentric disease, scleroderma, lupus • Chemo tx: for all node (+), cancers >1cm,and cancers >0.5cm with adverse prognostic features (BV or lymph invasion, high nuclear or histological grade, HER-2-neu amplification, & (-) hormone receptors • Tamoxifen: for hormone receptor (+), >1cm; 5yr tx if premenopausal; 1-2 yr tx then aromatase inhibitor if menopausal • Herceptin: for HER-2-neu (+) cancers

  34. Breast Cancer Treatment • Advanced Local-Regional (Stage IIIA or IIIB) • No clinically detected distant mets • Neoadjuvant chemo to shrink tumor & allow for breast conservation tx w/radiation (doxorubicin or taxane regimin • Most get Mastectomy with evaluation of axillary status followed by radiation, +/- chemo • SLNBx acceptable after neoadjuvant tx if no clinical nodes prior to chemo (need axillary dissection then) • Distant Metastases (Stage IV) • Tx mostly aimed at enhancing quality of life • Hormonal therapy: bone or soft tissue mets only and receptor (+) • Cytotoxic chemo: hormone receptor (-) or refractory, or symptomatic visceral mets • Bisphosphonates: bony mets

  35. Radiation Therapy • Can be used for all stages of Breast cancer • Reduces risk of local recurrence • Standard in breast conservation tx • Not needed for low-grade DCIS of the solid, cribiform, or papillary subtypes that is <0.5 cm & excised widely w/negative margins • Mastectomy radiation: positive margins, 4 or more lymph nodes positive (or 3 or more in premenopausal woman) • Chest wall & supraclavicular lymph nodes are radiated

  36. Surgical Approach- Breast Conservation • Resection of primary cancer with a 2mm margin of normal-appearing tissue + assessment of regional node status + radiation tx • Segmental mastectomy, lumpectomy, partial mastectomy, wide local excision • Use areolar incision when possible • Should be able to encompass in mastectomy incision if completion mastectomy needed • Upper breast lesion: follow lines of Zahn • Lower breast lesion: radial incision • Oncoplastic techniques if possible

  37. Surgical Approach- Mastectomy • Skin sparing: removes all breast tissue, NAC, & prev biopsy scars (recurrence rate 6-8%) • Total (simple): all breast tissue, NAC, skin • Modified radical: all breast tissue, NAC, skin & Level I & II axillary lymph nodes • Halstead radical: same as modified, with pectoralis major & minor removed & Level III nodes • Patey modification of MRM: removes pectoralis minor for dissection of Level III nodes • Skin flap thickness usu 7-8 mm • Complications: seroma (30%), hematoma, wound infection, skin flap necrosis • Lymphedema w/MRM: 10-20% (tx w/compression sleeve)

  38. Breast Reconstruction • Immediate for prophylactic mastectomy or early invasive cancer • Delayed for advanced cancer (radiation needed) • Immediate: Expander/Implant, or Autologous tissue (latissimus dorsi myocutaneous flap; abdominal TRAM or DIEP flap) • If 2 or less ribs resected, no recon needed (scar tissue provides stabilization)

  39. Special Situations • Breast CA in Pregnancy: usu present w/advanced disease; MRM in 1st & 2nd trimesters; lumpectomy w/axillary node dissection,radiation after delivery; chemo acceptable in 2nd & 3rd trimesters only • Male Breast CA: <1% of all breast CA; usu invasive ductal; highest in Jewish & African-Americans; preceded by gynecomastia in 20%; similar survival rates as women; tx similar to women • Phyllodes tumor: benign, borderline, or malignant; mammo findings cannot distinguish type; sharp demarcation from normal breast tissue; Tx w/lumpectomy or mastectomy; no axillary dissection needed • Inflammatory Breast CA: induration, erythema, & edema; invasion of dermal lymphatics classic finding; 75% have palpable lymph nodes;Tx is neoadjuvant chemo w/MRM, radiation, +/- adjuvant chemo; poor prognosis

More Related